» Articles » PMID: 24955215

The Normal Function of the Cancer Kinase Mirk/dyrk1B is to Reduce Reactive Oxygen Species

Overview
Journal Genes Cancer
Specialty Oncology
Date 2014 Jun 24
PMID 24955215
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Mirk kinase is a gene upregulated and sometimes amplified in pancreatic cancers and in ovarian cancers, but expressed at very low levels in most normal diploid cells except for skeletal muscle. The muscle cell function of Mirk kinase selected for by cancer cells is unknown. It is now shown that Mirk protein is expressed at low levels and is largely nuclear in cycling skeletal muscle C2C12 myoblasts, but is translocated to the cytoplasm and upregulated when myoblasts initiate differentiation, as shown by immunofluorescence staining and by cell fractionation. Either Mirk depletion or Mirk kinase inhibition increased ROS levels in cycling C2C12 myoblasts. However, Mirk protein is localized in the cytoplasm of mature muscle fibers, specifically in the fast twitch fibers of human skeletal muscle where toxic ROS levels are generated by muscle contraction. C2C12 myoblasts at high density in differentiation media fuse to form differentiated postmitotic myotubes that can contract. A Mirk kinase inhibitor induced a dose-dependent increase in ROS in this model for fast twitch fibers of human skeletal muscle. Efficient Mirk depletion in SU86.86 pancreatic cancer cells by an inducible shRNA decreased expression of eight antioxidant genes. Thus both cancer cells and differentiated myotubes utilize Mirk kinase to relieve oxidative stress.

Citing Articles

A safe haven for cancer cells: tumor plus stroma control by DYRK1B.

Ems M, Brichkina A, Lauth M Oncogene. 2025; 44(6):341-347.

PMID: 39863750 PMC: 11790486. DOI: 10.1038/s41388-025-03275-6.


Increased Myocardial MAO-A, Atrogin-1, and IL-1β Expression in Transgenic Mice with Pancreatic Carcinoma-Benefit of MAO-A Inhibition for Cardiac Cachexia.

Stelter K, Alabssi A, Bonaterra G, Schwarzbach H, Fendrich V, Slater E Biomedicines. 2024; 12(9).

PMID: 39335522 PMC: 11428447. DOI: 10.3390/biomedicines12092009.


Effects of Monoamino-Oxidase-A (MAO-A) Inhibition on Skeletal Muscle Inflammation and Wasting through Pancreatic Ductal Adenocarcinoma in Triple Transgenic Mice.

Schmich S, Keck J, Bonaterra G, Bertoune M, Adam A, Wilhelm B Biomedicines. 2023; 11(3).

PMID: 36979889 PMC: 10046345. DOI: 10.3390/biomedicines11030912.


Quiescent Cancer Cells-A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse.

Lindell E, Zhong L, Zhang X Int J Mol Sci. 2023; 24(4).

PMID: 36835173 PMC: 9959385. DOI: 10.3390/ijms24043762.


Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors.

Alexandrov V, Vilenchik M, Kantidze O, Tsutskiridze N, Kharchilava D, Lhewa P J Med Chem. 2022; 65(20):13784-13792.

PMID: 36239428 PMC: 9619999. DOI: 10.1021/acs.jmedchem.2c00988.


References
1.
Litovchick L, Florens L, Swanson S, Washburn M, DeCaprio J . DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev. 2011; 25(8):801-13. PMC: 3078706. DOI: 10.1101/gad.2034211. View

2.
Michaelson L, Shi G, Ward C, Rodney G . Mitochondrial redox potential during contraction in single intact muscle fibers. Muscle Nerve. 2010; 42(4):522-9. PMC: 3015179. DOI: 10.1002/mus.21724. View

3.
Deng X, Ewton D, Mercer S, Friedman E . Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation. J Biol Chem. 2004; 280(6):4894-905. DOI: 10.1074/jbc.M411894200. View

4.
Zou Y, Lim S, Lee K, Deng X, Friedman E . Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell migration and is negatively regulated by the Met adaptor Ran-binding protein M. J Biol Chem. 2003; 278(49):49573-81. DOI: 10.1074/jbc.M307556200. View

5.
Dhawan J, Helfman D . Modulation of acto-myosin contractility in skeletal muscle myoblasts uncouples growth arrest from differentiation. J Cell Sci. 2004; 117(Pt 17):3735-48. DOI: 10.1242/jcs.01197. View